酸性蓝90; 酸性艳蓝G; 亮蓝G; 考马士亮兰G-250; 考马斯亮兰G250; 康美赛蓝G250; 3-(((4-((4-((4-乙氧基苯基)氨基)苯基)(4-(乙基(3-磺酰苄基)亚氨基)-2-甲基环己-2,5-二烯-1-亚基)甲基)-3-甲基苯基)(乙基)氨基)甲基)苯磺酸钠; Acid Blue 90; CBB G-250; Cyanine G; PAGE BLUE G90; Coomassie Brilliant blue; Polar Blue G; Blue G 250; BRILLIANT BLUE; SERVA BLUE G; Brilliant Blue G; Sodium 3-(((4-((4-((4-ethoxyphenyl)amino)phenyl)(4-(ethyl(3-sulfonatobenzyl)iminio)-2-methylcyclohexa-2,5-dien-1-ylidene)methyl)-3-methylphenyl)(ethyl)amino)methyl)benzenesulfonate
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is an effective, selective, and ATP-competitive pan class I PI3K inhibitor, with IC50 values of 0.5 nM (PI3Kα), 0.7 nM (PI3Kδ), 3.7 nM (PI3Kβ), and 6.4 nM (PI3Kγ). It has >2000-fold selectivity over other kinases except mTOR, and exhibits excellent antitumor activity, primarily used in life sciences for research and potential clinical applications.
